Pharmaceutical for prevention and treatment of demyelinating disease
US8039253B2 · kind B2 · utility
Assignees
Inventors
Key dates
| Filing date | Jun 29, 2001 |
| Grant date | Oct 18, 2011 |
| Priority date | — |
| Expiry date | Jun 6, 2026 |
Classification
- Technology area (CPC A)Human Necessities
- CPC primaryA61P43/00
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
A pharmaceutical for prevention and treatment of demyelination-associated neural function impairing diseases contains erythropoietin as an active ingredient, and protectively act on the survival of oligodendrocytes, which form a myelin sheath, in cerebrovascular dementia typified by multiple sclerosis and Binswanger disease, diseases involving demyelination. The pharmaceutical and method also promote maturation of undifferentiated oligodendrocytes present in the brain, activating remyelination. Through these mechanisms, the pharmaceutical and method can prevent and treat demyelination-associated neural function impairing diseases.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.